Sutro Biopharma Future Growth
Future criteria checks 2/6
Sutro Biopharma is forecast to grow earnings and revenue by 12.8% and 27.4% per annum respectively while EPS is expected to grow by 21.4% per annum.
Key information
12.8%
Earnings growth rate
21.4%
EPS growth rate
| Biotechs earnings growth | 21.1% |
| Revenue growth rate | 27.4% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 03 Apr 2024 |
Recent future growth updates
Recent updates
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
May 07Sutro Biopharma EPS misses by $0.04, beats on revenue
May 07Sutro: Leading Cell Free Protein Synthesis Company With Promising Early Data
Jan 06Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Jan 06
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 93 | -250 | -199 | -109 | 9 |
| 12/31/2025 | 60 | -260 | -227 | -133 | 10 |
| 12/31/2024 | 72 | -217 | -239 | -102 | 10 |
| 12/31/2023 | 154 | -107 | -116 | -112 | N/A |
| 9/30/2023 | 49 | -172 | -156 | -150 | N/A |
| 6/30/2023 | 57 | -143 | -57 | -50 | N/A |
| 3/31/2023 | 75 | -130 | -29 | -22 | N/A |
| 12/31/2022 | 68 | -119 | -4 | 4 | N/A |
| 9/30/2022 | 70 | -123 | -1 | 6 | N/A |
| 6/30/2022 | 53 | -134 | -96 | -84 | N/A |
| 3/31/2022 | 53 | -114 | -101 | -87 | N/A |
| 12/31/2021 | 62 | -106 | -97 | -82 | N/A |
| 9/30/2021 | 60 | -127 | -93 | -79 | N/A |
| 6/30/2021 | 69 | -79 | -85 | -72 | N/A |
| 3/31/2021 | 50 | -43 | -88 | -79 | N/A |
| 12/31/2020 | 43 | -32 | -75 | -68 | N/A |
| 9/30/2020 | 46 | 13 | -70 | -62 | N/A |
| 6/30/2020 | 40 | -17 | -66 | -61 | N/A |
| 3/31/2020 | 41 | -61 | -68 | -64 | N/A |
| 12/31/2019 | 43 | -56 | -69 | -65 | N/A |
| 9/30/2019 | 51 | -42 | -60 | -58 | N/A |
| 6/30/2019 | 46 | -40 | 4 | 6 | N/A |
| 3/31/2019 | 41 | -38 | 6 | 8 | N/A |
| 12/31/2018 | 38 | -35 | 11 | 13 | N/A |
| 9/30/2018 | 23 | -49 | 12 | 14 | N/A |
| 6/30/2018 | 33 | -40 | -38 | -36 | N/A |
| 3/31/2018 | 42 | -30 | -40 | -37 | N/A |
| 12/31/2017 | 52 | -20 | -40 | -37 | N/A |
| 12/31/2016 | 60 | N/A | N/A | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STRO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: STRO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: STRO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: STRO's revenue (27.4% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: STRO's revenue (27.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if STRO's Return on Equity is forecast to be high in 3 years time